Drug search by name

Bortezomib Intravenous and PCE Dispertab

Determining the interaction of Bortezomib Intravenous and PCE Dispertab and the possibility of their joint administration.

Check result:

Bortezomib Intravenous <> PCE Dispertab

Relevance: 20.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Erythromycin may increase the blood levels of bortezomib. In some cases, this can increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, constipation, nerve damage, low blood pressure, heart failure, lung problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop numbness, burning, or tingling in the hands and feet; swelling; sudden, unexpected weight gain; shortness of breath; breathing difficulties; paleness; fatigue; dizziness; fainting; unusual bruising or bleeding; fever; chills; diarrhea; sore throat; muscle aches; blood in phlegm; weight loss; red or inflamed skin; body sores; and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme. In a study of 12 patients, administration of bortezomib with the potent inhibitor ketoconazole resulted in a 35% increase in mean bortezomib systemic exposure (AUC) compared to administration alone.

MANAGEMENT: Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.

References

Pekol T, Daniels JS, Labutti J, et al "Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites." Drug Metab Dispos 33 (2005): 771-7
"Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA.
Uttamsingh V, Lu C, Miwa GT, Gan LS "Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib." Drug Metab Dispos 33 (2005): 1723-8

Bortezomib Intravenous

Generic Name: bortezomib

Brand name: Velcade

Synonyms: Bortezomib (Intravenous)

What is Bortezomib Intravenous?

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

What is PCE Dispertab?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions